Vaccine Therapy in Treating Patients With Kidney Cancer
NCT00096629
Completed
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2018
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Kidney Cancer
Register for Updates
Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
NCT02141581
Completed
The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza vaccine (LAIV) administered intranasally -- all given to generally healthy male and female adult volunteers.
Gender:
ALL
Ages:
Between 8 years and 34 years
Trial Updated:
04/05/2018
Locations: Stanford LPCH Vaccine Program, Stanford, California
Conditions: Influenza
Register for Updates
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
NCT01954251
Completed
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/30/2018
Locations: GSK Investigational Site, Phoenix, Arizona +19 locations
Conditions: Herpes Zoster
Register for Updates
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
NCT01165203
Completed
This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational Herpes Zoster (HZ) vaccine GSK1437173A in Human Immunodeficiency Virus (HIV) infected subjects, firstly enrolling subjects treated with antiretroviral therapy (ART) and with high CD4 T cell counts, and subsequently ART-treated subjects with low CD4 T cell counts, and ART-naïve subjects with high CD4 T cell counts. This Protocol Posting has been updated following Amendment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2018
Locations: GSK Investigational Site, Long Beach, California +14 locations
Conditions: Herpes Zoster
Register for Updates
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
NCT01042535
Completed
This randomized phase I/II trial studies the side effects and best dose of vaccine therapy and to see how well it works when given together with 1-methyl-D-tryptophan (1-MT) in treating patients with metastatic breast cancer. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2018
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
NCT00654030
Completed
Rationale: Vaccines made from allogeneic tumor cells may help the body build an effective immune response to kill tumor cells. The Purpose of this study is to evaluate the effects of a lung cancer vaccine in patients with Stage I or Stage II Non-Small Cell Lung Cancer (NSCLC) after completion of initial definitive therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2018
Locations: Commonwealth Cancer Center, Danville, Kentucky +3 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
NCT02433652
Completed
Infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries, and the development of a dengue vaccine is a top health priority. This study will evaluate the ability of a single dose of a trivalent dengue vaccine to protect against infection with an attenuated candidate DENV-2 vaccine, administered 6 months after the trivalent dengue vaccine.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/27/2018
Locations: Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore, Maryland +1 locations
Conditions: Dengue
Register for Updates
Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use
NCT01784874
Completed
The aim of this study is to generate data on immunogenicity and safety of Purified Vero Rabies Vaccine - Serum Free (VRVg) in comparison with Imovax® Rabies in order to support the registration of VRVg in the USA. Primary Objectives: * To demonstrate that VRVg is non inferior to Imovax® Rabies in terms of proportion of subjects achieving an rabies virus neutralizing antibody (RVNA) titer ≥ 0.5 IU/mL at Day 42. * To demonstrate that the observed proportion of subjects achieving an RVNA titer ≥... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/05/2018
Locations: Not set, Redding, California +5 locations
Conditions: Rabies
Register for Updates
A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
NCT02553343
Completed
The aim of the study is to assess the safety and immunogenicity of two formulations of the high-dose quadrivalent influenza vaccine compared to the licensed high-dose trivalent influenza vaccine control in healthy elderly subjects aged 65 years of age and above. Primary objectives: * To describe the safety profile of all subjects in each study group. * To demonstrate that the high-dose quadrivalent influenza vaccine induces an immune response (as assessed by HAI geometric mean titers (GMTs) th... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2018
Locations: Not set, Milford, Connecticut +8 locations
Conditions: Influenza
Register for Updates
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma
NCT00101166
Completed
The purpose of this study is to find out what effects (good and/or bad) this new cancer vaccine has on the patient and their cancer, whether it is safe and whether it can help get rid of their cancer (malignant melanoma). We want to check how the patient's immune system reacts, both before and after the vaccine treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2018
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Melanoma (Skin)
Register for Updates
Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.
NCT00248833
Completed
The purpose of this study is to determine if the vaccine called Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is safe and free from side effects and if it will protect people from meningitis. This study will vaccinate three groups of people. In the first 2 groups, the study will be double-blinded. This means that neither the volunteer or the medical team will know which formulation of the vaccine was administered. The third group of volunteers and the medical team will know that they are rece... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/29/2018
Locations: Walter Reed Army Institute of Research, Clinical Trials Center, Silver Spring, Maryland
Conditions: Meningitis, Meningococcal, Serogroup B
Register for Updates
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
NCT00766753
Completed
This is a single-institution Phase I/II study designed to evaluate the safety and induction of an immune response, and preliminary clinical response of vaccinations with Type-1 alpha-DCs (alpha-DC1) loaded with glioma-associated antigen (GAA) epitopes and administration of poly-ICLC in patients with recurrent malignant gliomas. Approximately 30 subjects will be enrolled in this study at UPMC/UPCI Hillman Cancer Center. The study participants in this trial will be HLA-A2 positive male or female a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2018
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Malignant Glioma
Register for Updates